ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0736

Effectiveness of Tocilizumab in strokes in patients with giant cell arteritis. Spanish multicenter study of clinical practice
Abstract Number: 0737

Effectiveness and Safety of Janus Kinase Inhibitors in Giant Cell Arteritis. Real-World Clinical Practice Study and Literature Review
Abstract Number: 0738

Real World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell Arteritis
Abstract Number: 0739

Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations
Abstract Number: 0740

Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients
Abstract Number: 0741

Characteristics of African American vs. Non-African American Patients with Giant Cell Arteritis: A Retrospective Cohort Study
Abstract Number: 0742

Exploring Racial Variation in the Clinical Manifestations of Giant Cell Arteritis: A Retrospective Single-Center Study
Abstract Number: 0743

Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
Abstract Number: 0744

Age and Sex Influence on Clinical Manifestations of Giant Cell Arteritis: Results from the ARTESER Registry
Abstract Number: 0745

Prevalence and Clinical Significance of Low ESR and CRP in Giant Cell Arteritis: A Population Based Study
Abstract Number: 0746

Impact of Frailty on Mortality in GCA and PMR: A Retrospective Cohort
Abstract Number: 0747

Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis
Abstract Number: 0748

Does The Number Of Arteries Affected At The Disease Onset Predict Relapses Of Giant Cell Arteritis?
Abstract Number: 0749

Prevalence and characteristics of subclinical Polymyalgia Rheumatica in patients with Giant Cell Arteritis
Abstract Number: 0750

Fibrinogen as a biomarker in the diagnosis of giant cell arteritis and detection of flares

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].